Genprex, Inc. (GNPX)
NASDAQ: GNPX · Real-Time Price · USD
0.381
-0.019 (-4.65%)
Feb 24, 2025, 10:21 AM EST - Market open
Genprex Employees
Genprex had 26 employees as of December 31, 2023. The number of employees decreased by 2 or -7.14% compared to the previous year.
Employees
26
Change (1Y)
-2
Growth (1Y)
-7.14%
Revenue / Employee
n/a
Profits / Employee
-$873,460
Market Cap
3.24M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
GNPX News
- 5 days ago - Genprex Advances Diabetes Program with Addition of Research Focused on Non-Viral Delivery System - PRNewsWire
- 6 days ago - Genprex Provides Update on Diabetes Gene Therapy Program - PRNewsWire
- 11 days ago - Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - PRNewsWire
- 4 weeks ago - Genprex Announces First Patient Dosed in Phase 2 Expansion Portion of Acclaim-3 Clinical Study of Reqorsa® Gene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PRNewsWire
- 7 weeks ago - Genprex to Participate at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 2 months ago - Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer - PRNewsWire
- 3 months ago - Genprex Signs Exclusive License to Additional Gene Therapy Technologies with the University of Michigan for the Treatment of Lung Cancer - PRNewsWire
- 3 months ago - Genprex Collaborators Present Positive Preclinical Data on Reqorsa® Gene Therapy at the Society for Immunotherapy of Cancer 2024 Annual Meeting - PRNewsWire